Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004


Vega, JC; Sanchez, BF; Montero, LM; Montana, R; Mahecha, MD; Duenes, B; Baron, AR; Reithinger, R; (2007) Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004. Tropical medicine & international health, 12 (12). pp. 1540-1544. ISSN 1360-2276 DOI: https://doi.org/10.1111/j.1365-3156.2007.01962.x

Full text not available from this repository.

Abstract

We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277-488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226-21 532).

Item Type: Article
Keywords: Antiprotozoal Agents, economics, therapeutic use, Colombia, epidemiology, Cost-Benefit Analysis, Disease Outbreaks, economics, Hospital Costs, statistics & numerical data, Humans, Leishmaniasis, drug therapy, economics, epidemiology, Meglumine, economics, therapeutic use, Organometallic Compounds, economics, therapeutic use
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
Research Centre: Leishmaniasis Group
PubMed ID: 18076562
Web of Science ID: 251387300017
URI: http://researchonline.lshtm.ac.uk/id/eprint/7983

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
300Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item